Chemotherapy-induced peripheral neuropathy

Journal of the Peripheral Nervous System

Volumn 2, Issue 4, 1997, Pages 350-361

  Hilkens, Pieter H E ^a,b   Van Den Bent, Martin J ^b  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Neuropathy; Paclitaxel; Suramin; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; NEUROPROTECTIVE AGENT;

ANIMAL; CHEMICALLY INDUCED DISORDER; HUMAN; PATHOLOGY; PERIPHERAL NEUROPATHY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0031290235     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (143)

1. Hamers FPT, Gispen WH, Neijt JP: Neurotoxic side-effects of cisplatin. Eur. J. Cancer 1991; 27:372-376.
2. Bruckner HW, Wallach R, Cohen CJ, Deppe G, Kabakow B, Ratner L, Holland JF: High-dose platinum for the treatment of refractory ovarian cancer. Gynec. Oncol. 1981; 12:64-67.
3. Ozols RF, Ostchega Y, Myers CE, Young RC: High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J. Clin. Oncol. 1985; 3:1246-1250.
4. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, KudlaHatch V: High-dose cisplatin in advanced head and neck cancer. Cancer Chemother. Pharmacol. 1987; 19:155-158.
5. Mollman JE, Glover DJ, Hogan WM, Furman RE: Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61:2192-2195.
6. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P: Cisplatin neuropathy: clinical course and neurophysiological findings. J. Neurol. 1992; 239:199-204.
7. Hansen SW, Helweg-Larsen S, Trojaborg W: Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J. Clin. Oncol. 1989; 7:1457-1461.
8. Hovestadt A, Van der Burg MEL, Verbiest HBC, van Putten WLJ, Vecht CJ: The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J. Neurol. 1992; 239:143-146.
9. Hainsworth JD, Burnett LS, Jones HW III, Grosh WW, Johnson DH, Greco FA: High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J. Clin. Oncol. 1990; 8:502-508.
10. Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J. Clin. Oncol. 1985; 3:1373-1378.
11. Boogerd W, Ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJJF, Van der Sande JJ: Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J. Neuro-oncol. 1990; 9:255-263.
12. Hansen SW: Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. Br. Med. 1990; 300:511-512.
13. Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treat. Rep. 1984; 68:659-660.
14. Walsh TJ, Clark AW, Parhad IM, Green WR: Neurotoxic effects of cisplatin therapy. Arch. Neurol. 1982; 39:719-720.
15. Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cis-platinum (II) diamine-chloride (PDD) therapy in a thirty-year-old man. Cancer 1980; 45:764-766.
16. Cattaneo MT, Filipazzi V, Piazzi E, Damiani E, Mancarella G: Transient blindness and seizure associated with cisplatin therapy. J. Cancer Res. Clin. Oncol. 1988; 114:528-530.
17. Gershenson DM, Wharton JT, Herson J, Edwards CL, Rutledge FN: Single-agent cis-Platinum therapy for advanced ovarian cancer. Obstet. Gynecol. 1981; 58: 487-496.
18. Van Gelder T, Geurs Ph, Kho GS, Dippel DWJ, Vecht ChJ, Splinter TAW: Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur. J. Cancer 1993; 29A:1497-1498.
19. Schaefer SD, Post JD, Close LG, Wright CG: Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985; 56:1934-1939.
20. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984; 54:1269-1275.
21. Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 1986; 69:295-308.
22. Krarup-Hansen A, Fugleholm K, Hehveg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C: Examination of distal involvement in cisplatin-induced neuropathy in man. Brain 1993; 116:1017-1041.
23. Windebank AJ, Smith AG, Russell JW: The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44:488-494.
24. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34:934-938.
25. Gerritsen van der Hoop R, Van der Burg MEL, Ten Bokkel Huinink WW, van Houwelingen JC, Neijt JP: Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66:1697-1702.
26. Vecht CJ, Hovestadt A, Verbiest HBC, Van Putten WLJ, Neijt JP, van der Burg MEL: Org 2766 in the prevention of cisplatin neuropathy. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (Howell SB, ed.). New York: Plenum Press, 1991, pp. 501-508.
27. Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF: Cisplatin neuropathy with Lhermitte's sign. J. Neural. Neurosurg. Psychiatry 1986; 49:96-99.
28. Inbar M, Merimsky O, Wigler N, Chaitchik S: Cisplatin-related Lhermitte's sign. Anti-cancer Drugs 1992; 3:375-377.
29. Ongerboer de Visser BW, Tiessens G: Polyneuropathy induced by cisplatin. Prog. Exp. Tumor Res. 1985; 29:190-196.
30. List AF, Kummet TD: Spinal cord toxicity complicating treatment with cisplatin and etoposide. Am. J. Clin. Oncol. 1990; 13:256-258.
31. Walther PJ, Rossitch E, Bullard DE: The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer 1987; 60:2170-2172.
32. Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66:1117-1123.
33. Mollman JE, Hogan WM, Glover DJ, McCluskey LF: Unusual presentation of cis-platinum neuropathy. Neurology 1988; 38:488-490.
34. Grunberg SM, Sonka S, Stevenson LL, Muggia FM: Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother. Pharmacol. 1989; 25:62-64.
35. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin. Oncol. 1982; 9:103-130.
36. Hilkens PHE, Planting AST, Van der Burg MEL, Moll JWB, Van Putten WLJ, Vecht ChJ, van den Bent MJ: Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur. J. Neurol. 1994; 1:45-50.
37. Daugaard GK, Petrera J, Trojaborg W: Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol. Scand. 1987; 76:86-93.
38. Cowan JD, Kies MS, Roth JL, Joyce RP: Nerve conduction studies in patients treated with cis-Diaminedichloroplatinum(II): A preliminary report. Cancer Treat. Rep. 1980; 64:10-11.
39. Riggs JE, Ashraf M, Snyder RD, Gutmann L: Prospective nerve conduction studies in cisplatin therapy. Ann. Neurol. 1988; 23:92-94.
40. Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FGI: Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J. Neurol. Sci. 1989;93:167-174.
41. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69:203-207.
42. Ashraf M, Scotchel PL, Krall JM, Flink EB: cis-Platinum-induced hypomagnesemia and peripheral neuropathy. Gynec. Oncol. 1983; 16:309-318.
43. Holleran WM, DeGregorio MW: Evolution of high-dose cisplatin. Invest. New Drugs 1988; 6:135-142.
44. Blumenreich MS, Woodcock TM, Jones M, Richman SP, Gentile PS, Kubota TT, Allegra JC: High-dose cisplatin in patients with advanced malignancies. Cancer 1985; 55:1118-1122.
45. Salem P, Khalyl M, Jabboury K, Hashimi L: Cisdiaminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984; 53:837-840.
46. Mortimer JE, Schulman S, MacDonald JS, Kopecky K, Goodman G: High-dose cisplatin in disseminated melanoma: a comparison of two schedules. Cancer Chemother. Pharmacol. 1990; 25:373-376.
47. Gandara DR, DeGregorio MW, Wold H, Wilburg BJ, Kohler M, Lawrence HJ, Deisseroth AB, George CB: High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group pilot study in non-small cell lung cancer. J. Clin. Oncol. 1986; 4:1787-1793.
48. van den Bent MJ, Van der Burg MEL, Van Putten WLJ, van Raaij-van der Aarsen VJM, de Wit R, Kruit WHJ, Stoter G, Verweij J: Peripheral neurotoxicity is not a centra-indication for retreatment with dose intensive cisplatin therapy. J. Neuro-oncol. 1996; 30:123 (Abstract).
49. Himes RH, Kersey RN, Heller-Betinger I, Samson FE: Action of vinca alkaloids vincristine, vinblastine and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976; 36:3798-3802.
50. Rosenthal S, Kaufman S: Vincristine neurotoxicity. Ann. Int. Med. 1974; 80:733-737.
51. Sandler SG, Tobin W, Henderson WS: Vincristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology 1969; 19:367-374.
52. Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Schnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC: Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973; 33:1258-1264.
53. Whittaker JA, Griffith IP: Recurrent laryngeal nerve paralysis in patient receiving vincristine and vinblastine. Br. Med. J. 1977; 1:1251-1252.
54. Casey EB, Jellife AM, Le Quesne PM, Millett YL: Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96:69-86.
55. Watkins SM, Griffin JP: High incidence of vincristine-induced neuropathy in lymphomas. Br. Med. J. 1978; 1:610-612.
56. Legha SS: Vincristine neurotoxicity. Med. Toxicol. 1986; 1:421-427.
57. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ: Long term effects of vincristine on the peripheral nervous system. J. Clin. Oncol. 1993; 15:23-27.
58. Bradley WG, Lassman LP, Pearce GW, Walton JN: The neuromyopathy of vincristine in man. J. Neurol. Sci. 1970; 10:107-131.
59. Guiheneuc P, Ginet J, Groleau JY, Rojouan J: Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon with transitory enhancement of spinal transmission of the monosynaptic reflex. J. Neurol. Sci. 1980; 45: 355-366.
60. Gottschalk PG, Dyck PJ, Kiely JM: Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 1968; 18:875-882.
61. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in CharcotMarie-Tooth disease type 1A. Cancer 1996; 77:1356-1362.
62. Neumann Y, Toren A, Rechavi G, Seifried B, Shoham N, Mandel M, Kenet G, Sharon N, Sadeh M, Navon R: Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med. Ped. Oncol. 1996; 26:280-283.
63. Norman M, Elinder G, Finkel Y: Vincristine neuropathy and a Guillain-Barré syndrome: a case with acute lymphatic leukemia and quadriparesis. Eur. J. Haematol. 1987; 39:75-76.
64. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C: Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother. Pharmacol. 1996; 39:150-156.
65. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN: The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev. 1993; 19:351-386.
66. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N. Engl. J. Med. 1995; 332:1004-1014.
67. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 1979; 227: 665-667.
68. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacological study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 1993; 11:2010-2020.
69. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. 1992; 10:1165-1170.
70. Lipton RB, Apfel SC, Dutcher JP, Rosenburg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39:368-373.
71. Apfel SC, Lipton RB, Arezzo JC, Kessler JA: Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 1991; 29:87-90.
72. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993; 20:1-15.
73. Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, Martini C, Scaioli V: Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J. Natl. Cancer Inst. 1994; 86:1099-1101.
74. Perry JR, Warner E: Transient encephalopathy after paclitaxel (taxol) infusion. Neurology 1996; 46:1596-1599.
75. van Gerven JMA, Moll JWB, van den Bent MJ, Bontebal M, van der Burg MEL, Verweij J, Vecht ChJ: Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur. J. Cancer 1994; 30A:1074-1077.
76. Van den Bent MJ, van Raaij-van den Aarsen VJM, Verweij J, van Doom PAV, Sillevis Smitt PAE: Progression of paclitaxel induced neuropathy following discontinuation of treatment. Muscle Nerve 1997; 20:750-752.
77. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 1987; 5: 1232-1239.
78. Schaumburg HH, Spencer PS: Toxic neuropathies. Neurology 1979; 29:429-431.
79. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Taxol: the first of the taxanes, an important new class of anti-tumor agents. Semin. Oncol. 1992; 19:646-662.
80. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 1994; 35:304-311.
81. Sahenk Z, Barohn R, New P, Mendell JR: Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 1994; 51:726-729.
82. Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann. Oncol. 1995; 6:489-494.
83. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 1992; 10:1748-1753.
84. Pronk LC, Stoter G, Verweij J: Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects. Cancer Treat. Rev. 1995; 21:463-478.
85. Fossella F, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chase M, Shin DM, Glisson B, Benner B, Huber M, Perez-Soler R, Hong WK, Raber M: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 1994; 12:1238-1244.
86. Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of doceiaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 1994; 12:1232-1237.
87. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1995; 13:314-322.
88. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J: Docetaxel (taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group. Eur. J. Cancer 1994; 30A:1061-1064.
89. Hilkens PHE, Verweij J, Stoter G, Vecht ChJ, Van Putten WLJ, van den Bent MJ: Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46:104-108.
90. Hilkens PHE, Verweij J, Vecht ChJ, Stoter G, Van den Bent MJ: Clinical characteristics of severe peripheral neuropathy induced by docetaxel (taxotere). Ann. Oncol. 1997; 8:187-190.
91. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ: Neurotoxicity of docetaxel (taxotere). Neurology 1996; 46:108-111.
92. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM: Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47:115-118.
93. Van den Bent MJ, Hilkens PHE, Van Raaij-van der Aarsen VJM, Verweij J: Lhermitte's sign following chemotherapy with docetaxel. Neurology 1997 (in press).
94. New PZ, Barohn R: Neurotoxicity of taxotere. Neurology 1993;43:A191 (Abstract).
95. Pronk LC, Hilkens PHE, van den Bent MJ, Van Putten WLJ, Stoter G, Verweij J: Corticosteroid comedication does not reduce incidence and severity of neurotoxicity induced by docetaxel. (submitted)
96. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996; 334:1-6.
97. Cavaletti G, Tredici G: Platinum compounds and taxoids: is combination neurotoxicity a possibility? Cancer J. 1995; 8:46-47.
98. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, Hakes T: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin. Oncol. 1994; 12:2301-2308.
99. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995; 75:1141-1150.
100. Trimble EL, Adams JD, Hawkins MJ, Friedman JS, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 1993; 11: 2405-2410.
101. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin: a phase I and pharmacological study. J. Clin. Oncol. 1991; 9:1692-1703.
102. Connoly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynec. Oncol. 1996; 62:166-168.
103. Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G: Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J. Clin. Oncol. 1997; 15:199-206.
104. Hilkens PHE, Pronk LC, Verweij J, Vecht ChJ, Van Putten WLJ, van den Bent MJ: Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br. J. Cancer 1997; 75:417-422.
105. Pronk LC, Schellens JHM, Planting AST, Van den Bent MJ, Hilkens PHE, Van der Burg MEL, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J: A phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol. 1997; 15:1071-1079.
106. Hawkins F: Suramin: with special reference to onchocerciasis. Adv. Pharm. Chemother. 1978; 15:289-322.
107. Eisenberger MA, Reyno LM: Suramin. Cancer Treat. Rev. 1994; 20:259-273.
108. Myers C, Cooper M, Stein C, LaRocca R, Walther M, Weiss G, Choyke P, Dawson N, Steinber S, Uhrich M, Cassidy J, Kohler K, Trepel J, Linehan W: Suramin. A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 1992; 10:881-889.
109. Alberts D, Miranda E, Dorr R, Nichols N, Ketcam M, MacNeal W: Phase II and pharmacokinetic and human tumor cloning assay study of suramin in advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol. 1991; 10:187.
110. Russell JW, Windebank AJ, Podratz JL: Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann. Neurol. 1994; 36:221-228.
111. Stein CA, LaRocca R, McAtee N, Thomas R, Horne M, Myers CE: Suramin - an anti-cancer drug with a unique mechanism of action. J. Clin. Oncol. 1988; 7:499-508.
112. LaRocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC: Suramin-induced polyneuropathy. Neurology 1990; 40:954-960.
113. Baker WJ, Royer GL, Weiss RB: Cytarabine and neurological toxicity. J. Clin. Oncol. 1991; 9:679-693.
114. Boregeat A, De Muralt B, Stalder M: Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 1986; 58:852-854.
115. Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N. Engl. J. Med. 1974; 291:75-81.
116. Patel SR, Forman AD, Benjamin RS: High-dose Ifosfamide-induced exacerbation of peripheral neuropathy. J. Natl. Cancer Inst. 1994; 86:305-306.
117. Gandara DR, Perez EA, Wiebe V, DeGregorio MW: Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Semin. Oncol. 1991; 18:49-55.
118. Hamers FPT: Neurotrophic and neuroprotective agents in the prevention of toxic neuropathies.Thesis, 1992.
119. Hol EM, Mandys V, Sodaar P, Gispen WH, Bär PR: Protection by an ACTH(4-9) analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J. Neurosci. Res. 1994; 39:178-185.
120. Schmidt Y, Unger J, Bartke I, Reiter R: Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol of cisplatin treatment and in diabetic (db/db) mice. Exp. Neurol. 1995; 132:16-23.
121. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH: Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 1993; 53:544-549.
122. Apfel SC, Arezzo JC, Lipson LA, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 1992; 31:76-80.
123. Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL: Insulin-like growth factor-1: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993; 124:73-88.
124. Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 1995; 38:30-37.
125. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer; a randomized double blind placebo-controlled trial. J. Clin. Oncol. 1995; 13:26-32.
126. Planting AST, Catimel G, Mulder OHM, de Graeff A, Höppener F, Verweij J, Oster W, Vermorken JB: Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. (submitted) 1997.
127. Glover D, Glick JH, Weiler C, Fox K, Guerry D: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J. Clin. Oncol. 1987; 5:574-578.
128. Glover D, Grabelsky S, Fox K, Weiler C, Cannon L, Glick J: Clinical trials of WR-2721 and cis-platinum. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16:1201-1204.
129. Wadler S, Beitler JJ, Rubin JS, Haynes H, McGill F, Rozenblit A, Goldberg G, Cohen C, Speyer J, Runowicz C: Pilot trial of cisplatin, radiation, and WR 2721 in carcinoma of the uterine cervix: A New York gynecologic oncology group study. J. Clin. Oncol. 1993; 11:1511-1516.
130. Di Re F, Bohm S, Oriani S, Spatti GB, Pirovano C, Tedeschi M, Zunino F: High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann. Oncol. 1993; 4:55-61.
131. Hamers FPT, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH: Cisplatin-induced neuropathy in mature rats: effects of melanocortin-derived peptide Org 2766. Cancer Chemother. Pharmacol. 1993; 32: 162-166.
132. De Koning P, Gispen WH: Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 1987; 8:415-422.
133. Gerritsen van der Hoop R, De Koning P, Boven E, Neijt JP, Jennekens FGI, Gispen WH: Efficacy of the neuropeptide Org 2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur. J. Cancer Clin. Oncol. 1988; 24:637-642.
134. Gerritsen van der Hoop R, Vecht CJ, Van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, Van Houwelingen JC, Jennekens FGI, Gispen WH, Neijt JP: Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N. Engl. J. Med. 1990; 322:89-94.
135. Roberts JA, Jenison EL, Clarke-Pearson D, Langleben A: A randomized, multicenter, double-blind, placebo-controlled, dose finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. (submitted) 1997.
136. Van Gerven JMA, Hovestadt A, Moll JWB, Rodenburg CJ, Splinter TAW, Van Oosterom AT, Keizer L, Drogendijk TE, Groenhout CM, Vecht ChJ, Neijt JP: The effect of an ACTH(4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J. Neurol. 1994; 241:432-435.
137. Hilkens PHE, Van der Burg MEL, Moll JWB, van den Bent MJ, Van Putten WLJ, Vecht ChJ: Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study. Clin. Neural. Neurosurg. 1995; 97:139-141.
138. Kiburg B, Moorer-van Delft CM, Heimans JJ, Huijgens PC, Boer HH: In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4-9) analogue Org 2766. J. Neuro-oncol. 1996; 30:173-180.
139. Van Kooten B, Van Diemen HAM, Groenhout KM, Huijgens PC, Ossenkoppele GJ, Nauta JJP, Heimans JJ: A pilot study on the influence of a corticotropin (4-9) analogue on vinca alkaloid-induced neuropathy. Arch. Neurol. 1992; 49:1027-1031.
140. Hamers FPT, Pette C, Neijt JP, Gispen WH: The ACTH(4-9) analog, Org 2766, prevents taxol-induced neuropathy in rats. Eur. J. Pharmacol. 1993; 233:177-178.
141. Hayakawa K, Sobue G, Itoh T, Mitsuma T: Nerve growth factor prevents neurotoxic effects of cisplatin vincristine and taxol, on adult rat sympathetic ganglion expiants in vitro. Life Sci. 1994; 55:519-525.
142. Peterson ER, Crain SM: Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice. Science 1982; 217:377-379.
143. Apfel SC, Arezzo JC, Lewis ME, Kessler JA: The use of insulin-like growth factor I in the prevention of vincristine induced neuropathy in mice. Ann. N.Y. Acad. Sci. 1993; 692:243-245.